Transgenomic, Inc. Reports Poster Presentation At CAP ’15 Highlighting Joint Project To Detect Actionable Mutations In Tumors From Metastatic Colorectal Cancer Patients

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO) today announced that it presented a poster last week at CAP ’15, the annual meeting of the College of American Pathologists. The poster, which was co-authored by researchers from Transgenomic and Amgen, reported on the results of analysis of tumor tissue from two randomized clinical trials using Sanger sequencing. The analysis concluded that the use of validated assays, relevant controls, and assay-specific tissue requirements resulted in highly reproducible Sanger sequencing data from the FFPE clinical specimens.1

Help employers find you! Check out all the jobs and post your resume.